Background: Recent studies have shown that a special extract from Cistus x incanus L. Pandalis (Cystus Pandalis® extract) has proven to be effective against SARS-CoV-2 in vitro and it is likely that the extract shows to be effective against other new variants of SARS-CoV-2 like the “Indian” Delta-Variety as well. Methods: In order to verify our claim, we examined how the extract Cystus Pandalis® inhibits the cytopathic action (CPE) of the Coronavirus in a cell model with human intestinal cells (Caco-2). We incubated viruses with the extract and mixed them with the cell cultures. Result: Cystus Pandalis® extract has almost completely inhibited virus growth at concentrations greater than 100 μg/ml. The calculated IC50 (mean inhibitory concentration) for the "Indian" Delta variant was 101 µg/ml. Conclusion: Cistus x incanus L. Pandalis extract (Cystus Pandalis® extract) is capable of preventing cell cultures from being infected by SARS-CoV-2 in-vitro. Because of its high in-vitro potency against the new variants of SARS-CoV-2, it is more than ever reasonable to use Cystus Pandalis® prophylactically in order to decrease the virus load. The development of resistance to the extract is not likely. People tolerate the extract very well. No significant side effects have been detected. Phytopharmaceuticals extraxted from Cistus x incanus L. Pandalis are able to combat viral infections and can help contain future pandamics by being handed in advance profilactically.
| Published in | Journal of Diseases and Medicinal Plants (Volume 7, Issue 3) |
| DOI | 10.11648/j.jdmp.20210703.13 |
| Page(s) | 82-86 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2024. Published by Science Publishing Group |
Cystus Pandalis®, Virus Infection, SARS-CoV-2, Variants, Cistus Incanus, Delta
| [1] | DAZ: Mutanten und Virusevolution - Kann Impfen Resistenzen fördern? 31.03.2021 https://www.deutsche-apotheker-zeitung.de/news/artikel/2021/03/31/kann-impfen-resistenzen-foerdern/chapter:1. |
| [2] | Sanjuán R, Nebot MR, Chirico N, Mansky LM, Belshaw R.: Viral mutation rates. J Virol. 2010 Oct; 84 (19): 9733-48. doi: 10.1128/JVI.00694-10. Epub 2010 Jul 21. |
| [3] | Jo, W. K., Drosten, C., & Drexler, J.: The evolutionary dynamics of endemic human coronaviruses, Virus Evolution, Volume 7, Issue 1, January 2021, https://doi.org/10.1093/ve/veab020. |
| [4] | Read AF, Baigent SJ, Powers C, Kgosana LB, Blackwell L, et al.: Imperfect Vaccination Can Enhance the Transmission of Highly Virulent Pathogens. PLOS Biology 13 (7): e1002198. https://doi.org/10.1371/journal.pbio.1002198 (2015). |
| [5] | Pott R: Polymorphismus bei Cistrosen: Welche Varietät ist als Heilmittel tauglich? KFN-Pressekonferenz, Vortrag, 8. 11. 2006. |
| [6] | Petereit F.: Polyphenolische Inhaltsstoffe und Untersuchungen zur entzündungshemmenden Aktivität der traditionellen Arzneipflanze Cistus incanus L. (Cistaceae). Dissertation, Universität Münster, 1992. |
| [7] | Ehrhardt C, Hrincius ER, Korte V, Mazur I, Droebner K, et al.: A polyphenol rich plant extract, CYSTUS052, exerts anti influenza virus activity in cell culture without toxic side effects or the tendency to induce viral resistance. Antiviral research 2007, 76 (1), 38-47. doi: 10.1016/j.antiviral.2007.05.002. |
| [8] | Rebensburg S, Helfer M, Schneider M, Koppensteiner H, Eberle J, et al.: Potent in vitro antiviral activity of Cistus incanus extract against HIV and Filoviruses targets viral envelope proteins. Scientific reports 2016, 6, 20394. doi: 10.1038/srep20394. |
| [9] | Traeder JM: Antivirale Eigenschaften des Extrakts aus Cistus×incanus L. Pandalis auch bei SARS-CoV-2 in vitro nachgewiesen. Zeitschrift für Phytotherapie 2021; 42 (03): 121-126, DOI: 10.1055/a-1302-6097. |
| [10] | Traeder JM: Extract from Cistus × Incanus L. Pandalis also Effective against “British” Alpha (B. 1.1.7) and “South African” Beta (B. 1.351) SARS-CoV-2 Variants, Journal of Diseases and Medicinal Plants. Vol. 7, No. 2, 2021, pp. 44-47. doi: 10.11648/j.jdmp.20210702.13. |
| [11] | Mhatre S, Srivastava T, Naik S, Patravale V.: Antiviral activity of green tea and black tea polyphenols in prophylaxis and treatment of COVID-19: A review [published online ahead of print, 2020 Jul 17]. Phytomedicine. 2020; 153286. |
| [12] | Riehle P: Phenolische Inhaltsstoffe in C. incanus Tee – Charakterisierung und Stabilität innerhalb der Teezubereitung. Dissertation Universität Hamburg (2014). |
| [13] | Kalus U, Grigorov A, Kadecki O, Jansen JP, Kiesewetter H, et al.: Cistus incanus (CYSTUS052) for treating patients with infection of the upper respiratory tract: a prospective, randomised, placebo-controlled clinical study. Antiviral research 2009, 84 (3), 267-271. doi: 10.1016/j.antiviral.2009.10.001. |
| [14] | Kalus U, Kiesewetter H, Radtke H.: Effect of CYSTUS052 and green tea on subjective symptoms in patients with infection of the upper respiratory tract. Phytother Res. 2010 Jan; 24 (1): 96-100. doi: 10.1002/ptr.2876. PMID: 19444821. |
| [15] | Traeder JM: Zistrosenextrakt zur Prophylaxe. Erfahrungsheilkunde 2021; 70: 204-208. Thieme, Stuttgart. |
APA Style
Jens-Martin Traeder. (2021). Cistus × Incanus L. Pandalis Is Highly Effective Against Delta Variant of SARS-CoV-2 in Vitro. Journal of Diseases and Medicinal Plants, 7(3), 82-86. https://doi.org/10.11648/j.jdmp.20210703.13
ACS Style
Jens-Martin Traeder. Cistus × Incanus L. Pandalis Is Highly Effective Against Delta Variant of SARS-CoV-2 in Vitro. J. Dis. Med. Plants 2021, 7(3), 82-86. doi: 10.11648/j.jdmp.20210703.13
AMA Style
Jens-Martin Traeder. Cistus × Incanus L. Pandalis Is Highly Effective Against Delta Variant of SARS-CoV-2 in Vitro. J Dis Med Plants. 2021;7(3):82-86. doi: 10.11648/j.jdmp.20210703.13
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.jdmp.20210703.13,
author = {Jens-Martin Traeder},
title = {Cistus × Incanus L. Pandalis Is Highly Effective Against Delta Variant of SARS-CoV-2 in Vitro},
journal = {Journal of Diseases and Medicinal Plants},
volume = {7},
number = {3},
pages = {82-86},
doi = {10.11648/j.jdmp.20210703.13},
url = {https://doi.org/10.11648/j.jdmp.20210703.13},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.jdmp.20210703.13},
abstract = {Background: Recent studies have shown that a special extract from Cistus x incanus L. Pandalis (Cystus Pandalis® extract) has proven to be effective against SARS-CoV-2 in vitro and it is likely that the extract shows to be effective against other new variants of SARS-CoV-2 like the “Indian” Delta-Variety as well. Methods: In order to verify our claim, we examined how the extract Cystus Pandalis® inhibits the cytopathic action (CPE) of the Coronavirus in a cell model with human intestinal cells (Caco-2). We incubated viruses with the extract and mixed them with the cell cultures. Result: Cystus Pandalis® extract has almost completely inhibited virus growth at concentrations greater than 100 μg/ml. The calculated IC50 (mean inhibitory concentration) for the "Indian" Delta variant was 101 µg/ml. Conclusion: Cistus x incanus L. Pandalis extract (Cystus Pandalis® extract) is capable of preventing cell cultures from being infected by SARS-CoV-2 in-vitro. Because of its high in-vitro potency against the new variants of SARS-CoV-2, it is more than ever reasonable to use Cystus Pandalis® prophylactically in order to decrease the virus load. The development of resistance to the extract is not likely. People tolerate the extract very well. No significant side effects have been detected. Phytopharmaceuticals extraxted from Cistus x incanus L. Pandalis are able to combat viral infections and can help contain future pandamics by being handed in advance profilactically.},
year = {2021}
}
TY - JOUR T1 - Cistus × Incanus L. Pandalis Is Highly Effective Against Delta Variant of SARS-CoV-2 in Vitro AU - Jens-Martin Traeder Y1 - 2021/09/08 PY - 2021 N1 - https://doi.org/10.11648/j.jdmp.20210703.13 DO - 10.11648/j.jdmp.20210703.13 T2 - Journal of Diseases and Medicinal Plants JF - Journal of Diseases and Medicinal Plants JO - Journal of Diseases and Medicinal Plants SP - 82 EP - 86 PB - Science Publishing Group SN - 2469-8210 UR - https://doi.org/10.11648/j.jdmp.20210703.13 AB - Background: Recent studies have shown that a special extract from Cistus x incanus L. Pandalis (Cystus Pandalis® extract) has proven to be effective against SARS-CoV-2 in vitro and it is likely that the extract shows to be effective against other new variants of SARS-CoV-2 like the “Indian” Delta-Variety as well. Methods: In order to verify our claim, we examined how the extract Cystus Pandalis® inhibits the cytopathic action (CPE) of the Coronavirus in a cell model with human intestinal cells (Caco-2). We incubated viruses with the extract and mixed them with the cell cultures. Result: Cystus Pandalis® extract has almost completely inhibited virus growth at concentrations greater than 100 μg/ml. The calculated IC50 (mean inhibitory concentration) for the "Indian" Delta variant was 101 µg/ml. Conclusion: Cistus x incanus L. Pandalis extract (Cystus Pandalis® extract) is capable of preventing cell cultures from being infected by SARS-CoV-2 in-vitro. Because of its high in-vitro potency against the new variants of SARS-CoV-2, it is more than ever reasonable to use Cystus Pandalis® prophylactically in order to decrease the virus load. The development of resistance to the extract is not likely. People tolerate the extract very well. No significant side effects have been detected. Phytopharmaceuticals extraxted from Cistus x incanus L. Pandalis are able to combat viral infections and can help contain future pandamics by being handed in advance profilactically. VL - 7 IS - 3 ER -
Information
Email: